Clinical Trial Update: Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF [Phase 2]

View source ↗

Summary

Phase 2 pharmacokinetic and pharmacodynamic study of IDN-6556 in acute liver failure conditions was terminated, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alcoholic Hepatitis
• Liver Cirrhosis
• Liver Failure
• On Chronic Liver Failure

Drugs mentioned

• IDN-6556

Snippet

Sponsor: Conatus Pharmaceuticals Inc. | Conditions: Acute on Chronic Hepatic Failure, Acute Liver Failure | Phase 2 | Status: TERMINATED | Results posted: 2016-04-11